Exelixis (NASDAQ:EXEL) is scheduled to be announcing its earnings results after the market closes on Wednesday, July 31st. Analysts expect the company to announce earnings of $0.27 per share for the quarter.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.24. The company had revenue of $215.49 million for the quarter, compared to analysts’ expectations of $206.06 million. Exelixis had a return on equity of 37.21% and a net margin of 75.97%. Exelixis’s quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the firm earned $0.40 earnings per share. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
NASDAQ EXEL opened at $21.01 on Tuesday. The company has a quick ratio of 7.48, a current ratio of 7.56 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $6.34 billion, a PE ratio of 14.69, a PEG ratio of 0.47 and a beta of 1.93. Exelixis has a 1 year low of $13.42 and a 1 year high of $25.31. The business has a 50-day simple moving average of $20.96.
In other Exelixis news, CEO Michael Morrissey sold 34,721 shares of Exelixis stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $21.37, for a total transaction of $741,987.77. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Peter Lamb sold 217,404 shares of Exelixis stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $20.59, for a total value of $4,476,348.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 565,703 shares of company stock worth $11,624,139. Insiders own 4.50% of the company’s stock.
Several analysts recently issued reports on EXEL shares. Cowen reissued a “buy” rating on shares of Avrobio in a research note on Monday, July 15th. ValuEngine raised United States Steel from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 24th. BidaskClub cut Westport Fuel Systems from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. Morgan Stanley lifted their price objective on Zynga and gave the company an “overweight” rating in a research report on Thursday, May 2nd. Finally, Zacks Investment Research cut Great Portland Estates from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Exelixis has an average rating of “Hold” and an average target price of $28.38.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: What is a front-end load?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.